Stockreport

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte, Inc.  (HUMA) 
PDF - Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Com [Read more]